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Abstract
Background: Congenital fibrinogen deficiency is an ultra-rare disorder in which pa-
tients can experience severe and/or frequent bleeding episodes (BEs). Here, we pre-
sent the largest prospective study to date on the treatment of this disorder.
Methods: Hemostatic efficacy of human fibrinogen concentrate (HFC; FIBRYGA®, 
Octapharma AG) for treatment of bleeding or surgical prophylaxis was assessed 
by investigators and adjudicated by an independent data monitoring and end-
point adjudication committee (IDMEAC) according to a four-point scale, using 
objective criteria. Thromboelastometry maximum clot firmness (MCF) was also 
determined.
Results: Twenty-five afibrinogenemia patients were treated with HFC: 24 for on-
demand treatment of 89 BEs, and nine as prophylaxis for 12 surgeries. For BEs, 
treatment success (rating of excellent or good) evaluated by investigators was 
96.6% (90% confidence interval [CI], 0.92-0.99; two missing ratings, classified as 
failures) and by the IDMEAC was 98.9% (90% CI, 0.95-0.999). Mean ± standard 
deviation (SD) increase in MCF was 5.8 ± 2.5 mm one hour after the first HFC infu-
sion (mean ± SD dose, 61.88 ± 11.73 mg/kg). For the 12 surgeries (median [range] 
HFC dose/surgery, 85.80 mg/kg [34.09-225.36]), intraoperative and postopera-
tive treatment success were both rated 100% (90% CI, 0.82-1.00) by investigators 
and the IDMEAC. Three adverse events were possibly treatment related, includ-
ing a moderate case of thrombosis. There were no deaths, no severe allergic or 
hypersensitivity reactions, and no clinical evidence of neutralizing antifibrinogen 
antibodies.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and 
Haemostasis
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1  | INTRODUC TION
Fibrinogen, a 340 kDa glycoprotein, plays a central role in hemosta-
sis, specifically in clot formation and stabilization.1 Congenital fibrino-
gen disorders are rare, affecting approximately 1 to 2 in every million 
people in the general population.2 Whereas healthy individuals have 
a plasma fibrinogen level ranging from 150-450 mg/dL,3 those with 
afibrinogenemia and hypofibrinogenemia have an absence or low level 
(<150 mg/dL) of circulating fibrinogen, respectively.4 The incidence of 
spontaneous or trauma-related bleeding episodes (BEs) associated with 
congenital fibrinogen deficiency is variable, with the severity ranging 
from mild to catastrophic.2,4 Afibrinogenemia and/or more severe hy-
pofibrinogenemia (ie, fibrinogen < 10 mg/dL) are often associated with 
bleeding in the nose, gastrointestinal tract, joints, and uterus (heavy 
menstrual bleeding).2 Despite low levels of fibrinogen activity, annual 
incidence of bleeding in some patients with inherited afibrinogenemia 
or hypofibrinogenemia can be low, typically less than once per year.2
Standard treatment for bleeding patients with congenital fibrin-
ogen deficiency is fibrinogen replacement, targeted to a plasma fi-
brinogen level of 100-150 mg/dL.4,5 Therapies include fresh-frozen 
plasma (FFP), cryoprecipitate, and human fibrinogen concentrate 
(HFC). FFP requires thawing and donor–recipient ABO compatibility 
blood matching before administration and it has a low and variable 
fibrinogen content (and variable levels of other coagulation factors), 
which prevents precise dosing.6 Fibrinogen replacement with FFP 
necessitates a large transfusion volume, which is associated with a 
risk of volume overload.5,6 Furthermore, FFP most often does not un-
dergo pathogen inactivation, and therefore carries a risk of pathogen 
infection, and contains antigens and antibodies, which could elicit ad-
verse immunological or allergic reactions including the risk of trans-
fusion-related acute lung injury.6 Cryoprecipitate is a human plasma 
derivative that requires cross-matching and thawing prior to adminis-
tration and has a higher and slightly less variable fibrinogen concentra-
tion than FFP.6,7 Cryoprecipitate is pooled from multiple donors and is 
therefore associated with safety concerns, including risk of pathogen 
transmission (no viral inactivation) and transfusion-related acute lung 
injury.5-7 Consequently, cryoprecipitate has been withdrawn from 
most European countries, although it remains available in several oth-
ers, for example the United States, the UK, and Canada.6,7
Owing to the limitations of FFP and cryoprecipitate, HFC has be-
come the preferred option for replacement of fibrinogen in cases 
of congenital fibrinogen deficiency,5 and the replacement therapy 
of choice in patients with afibrinogenemia.8 Advantages of HFC 
over FFP and cryoprecipitate include faster preparation (no thaw-
ing required; no need for blood matching), faster administration (low 
infusion volume), and greater purity.6 Furthermore, the fibrinogen 
content of HFC is more consistent and can be accurately determined, 
thereby allowing standardized dosing.6 HFC can be considered safer 
than FFP and cryoprecipitate, with no risk of volume overload and 
reduced risk of pathogen transmission.6
Fibrinogen concentrates have been shown to be efficacious 
for the treatment of bleeding and surgical prophylaxis, while 
demonstrating a good safety profile.9-12 The HFC used in this 
trial was a state-of-the-art lyophilized plasma-derived concen-
trate (FIBRYGA®, Octapharma AG) that provides high purity and 
pathogen safety through two virus inactivation/elimination steps 
(solvent/detergent treatment and nanofiltration).5,13 The pharma-
cokinetic (PK) profile of this HFC was previously investigated in 
a randomized, cross-over comparative study. The PK properties 
were broadly comparable between the new HFC and a currently 
marketed comparator HFC (Haemocomplettan® P [RiaSTAP®]), 
with the exception of AUCnorm, which was significantly larger, and 
clearance, which was significantly slower, for the new HFC in pa-
tients with afibrinogenemia.14 The HFC used in this study is now 
licensed in multiple countries for the treatment of acute bleeding 
and for surgical prophylaxis in patients with fibrinogen deficiency, 
with approval obtained on the basis of a planned interim analysis 
of the present study.15 Here, we report the results from the final 
analysis, which aims to evaluate the efficacy and safety of HFC for 
on-demand treatment of acute bleeding episodes in the largest 
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Essentials
• This the largest prospective interventional study in con-
genital fibrinogen deficiency to date.
• Hemostatic efficacy of human fibrinogen concentrate 
(HFC) is assessed in afibrinogenemia patients.
• HFC was efficacious for both on-demand treatment of 
bleeding and surgical prophylaxis (n = 25).
• HFC had a favorable safety profile in patients with con-
genital afibrinogenemia.
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data collection available to date from a prospective interventional 
study of patients with congenital fibrinogen deficiency.
2  | METHODS
2.1 | Study design
This study (FORMA-02, NCT02267226) was a prospective, multi-
center, open label, uncontrolled Phase 3 efficacy and safety study in 
patients with congenital fibrinogen deficiency. Twelve centers across 
Bulgaria, India, Iran, Lebanon, Russia, Saudi Arabia, Turkey, the United 
States, and the UK participated in this study between October 2014 
and February 2018. Patients received HFC (FIBRYGA®; Octapharma 
AG) via intravenous infusion for on-demand treatment of bleeding 
or as surgical prophylaxis. HFC dosing was individually calculated for 
each patient based on baseline fibrinogen activity levels measured 
at the local laboratory and target plasma fibrinogen concentrations 
of 100 mg/dL (recommended lower limit of 80 mg/dL) for minor 
bleeding or minor surgery and 150 mg/dL (recommended lower limit 
of 130 mg/dL) for major bleeding or major surgery. The final deci-
sion on dosing was at the discretion of the treating physician. After 
each infusion, patients were monitored for ≥3 days for minor bleed-
ing or minor surgery or ≥7 days for major bleeding or major surgery. 
Patients treated on-demand for bleeding were monitored for a 30-
day safety follow-up period.
The study was conducted in accordance with Good Clinical 
Practice (CPMP/ICH/135/95), the Declaration of Helsinki and its 
amendments, and national law. The study protocol received ap-
proval from the appropriate national regulatory bodies, institu-
tional review boards, and independent ethics committees for each 
institution. All patients provided written informed consent before 
participating.
2.2 | Study population
Patients ≥12 years old (≥18 years in Russia) were enrolled if they 
had documented congenital afibrinogenemia or severe hypofi-
brinogenemia (defined as historical plasma fibrinogen activity 
of <50 mg/dL, or levels below the limit of detection of the local 
assay method) and were expected to require on-demand treat-
ment for an acute BE or were planning to undergo surgery. Key 
exclusion criteria were a bleeding disorder other than congenital 
fibrinogen deficiency, including dysfibrinogenemia; life expec-
tancy of <6 months; any coagulation-active drug within 1 week 
prior to start of treatment; hypersensitivity to human plasma pro-
teins; deep vein thrombosis (DVT), pulmonary embolism, or arte-
rial thrombosis within 1 year prior to start of treatment; diagnosis 
or suspicion of neutralizing antifibrinogen antibody currently or 
in the past; and regular prophylaxis with a fibrinogen-containing 
product.
2.3 | Evaluation of hemostatic efficacy
The investigator's clinical assessment of hemostatic efficacy for 
all BEs treated with HFC during the study period was based on a 
4-point objective scale (excellent, good, moderate, and none; Table 
S1). Previous studies demonstrated the utility of objective criteria 
for the clinical investigation of other congenital bleeding disor-
ders.16,17 All clinical efficacy assessments were adjudicated by an 
independent data monitoring and endpoint adjudication committee 
(IDMEAC) according to the same 4-point objective scale using data 
collected from the case report forms and information provided by 
the investigator. Overall treatment success was defined as a rating 
of excellent or good.
The primary endpoint was efficacy in the treatment of the first 
BE for each patient. To evaluate the efficacy of HFC for surgical pro-
phylaxis, intraoperative and postoperative efficacy were assessed 
by the surgeon and hematologist, based on objective 4-point scales, 
which included a comparison of predicted and actual blood loss 
(Tables S2 and S3). Efficacy ratings were additionally adjudicated by 
the IDMEAC. Overall treatment success was defined as a rating of 
excellent or good.
2.4 | Clot strength
Maximum clot firmness (MCF) was assessed as a surrogate measure 
of hemostatic efficacy. Plasma samples were prepared from blood 
taken prior to the first infusion for treatment of BEs and at 1 hour 
after the end of the infusion. For consistency, frozen samples were 
transferred to a central laboratory for testing. MCF was determined 
by performing thromboelastometry (ROTEM) on thawed plasma 
samples, as previously described.10,14
2.5 | Fibrinogen level and in vivo recovery
Fibrinogen plasma level was evaluated at the central laboratory 
using the Clauss assay. Incremental in vivo recovery (IVR) was cal-
culated as the maximum increase in plasma fibrinogen between 
pre-infusion and 1 hour post-infusion, divided by the exact dose 
of HFC.
2.6 | Safety
All adverse events (AEs) occurring during the study period were re-
corded. Treatment-emergent AEs (TEAEs) were defined as AEs oc-
curring between the start of the first HFC infusion and the end of 
each 30-day observation and follow-up period or during the surgical 
observation period, and were absent prior to treatment or worsened 
relative to the pre-treatment state. Non-TEAEs were those that oc-
curred outside of follow-up periods.
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Thrombogenicity measurements were performed at the central 
laboratory on plasma samples prepared from blood taken prior to 
the first infusion of HFC, 1 hour and 3 hours post-infusion and 1 
day after last infusion. Prothrombin fragments 1 and 2 (F1 + F2) and 
D-dimer levels were assessed.
Blood was drawn for immunogenicity testing on Day 1, prior 
to the first infusion of HFC, and Days 14 and 30 after infusion. An 
experimental enzyme-linked immunosorbent assay (ELISA) was de-
veloped for identification of antifibrinogen antibodies, with analysis 
performed at the central laboratory. Specific tests for neutralizing 
antifibrinogen antibodies were not performed.
2.7 | Statistical analysis
Categorical variables are presented as absolute values and per-
centages. Continuous variables are presented as mean ± standard 
deviation (SD) or median (range). For evaluation of hemostatic effi-
cacy, the lower limit of the two-sided 90% confidence intervals (CI) 
for success rate were calculated according to Blyth–Still–Casella 
interval for the proportion of patients with successful hemostatic 
efficacy (rating of excellent or good). Missing assessments were 
counted as failures. As the number of patients with this indication 
is very low, no formal sample size calculation was carried out; how-
ever, comparing the probabilities for different outcomes gave a suc-
cess rate of 90% for a total of 24 patients together with respective 
90% CIs. Statistical analysis was performed using SAS version 9.3.
3  | RESULTS
3.1 | Patient characteristics
Thirty-three patients were enrolled in the study, 25 of whom re-
ceived at least one infusion of HFC (Safety Population; Figure 1). 
Of these, 24 patients received HFC for treatment of one or more 
BEs (Bleeding Population; 89 BEs in total) and nine received HFC as 
surgical prophylaxis (Surgical Prophylaxis Population; 12 surgeries in 
total). Eight patients received HFC for bleeding and surgery, while 
one was treated for surgery only. The study was open for patients 
with hypofibrinogenemia or afibrinogenemia, but only patients with 
afibrinogenemia were enrolled.
The median (range) age of the Safety Population was 
27 years (12-54), with six patients (24%) aged 12-17 years 
(Table 1). Fourteen patients (56%) were male. All patients (100%) 
had afibrinogenemia.
3.2 | Hemostatic efficacy for on-demand 
treatment of bleeding
Of the 89 BEs treated with HFC, 87 were classed as minor. A full list 
of all BEs is given in Table S4. These included hemarthrosis or su-
perficial muscle, soft tissue, or oral bleeding. Two BEs were classed 
as major: a spontaneous intracranial hemorrhage and a spontane-
ous occult gastrointestinal bleed. Sixty-seven BEs were spontane-
ous and 22 were due to trauma. The mean (±SD) first dose of HFC 
administered per BE was 61.88 mg/kg (±11.73), while the total dose 
per BE was 65.51 mg/kg (±26.47; Table 2). In total, 100 infusions 
were administered, with 93.3% of BEs treated with a single infusion.
Investigator-assessed hemostatic efficacy was excellent for 70 
BEs (78.7%), good for 16 (18.0%), and moderate for one BE (1.1%) 
(Figure 2). Efficacy ratings by the investigator were missing for two 
BEs, one simultaneous with surgery, and one lost to follow-up. The 
IDMEAC was able to assess hemostatic efficacy for all 89 BEs. The 
F I G U R E  1   Patient disposition and analysis populations. 
*Patients who were screened and gave consent; †Patients who 
received at least one infusion of fibrinogen concentrate for 
treatment of a BE or surgical prophylaxis. Eight patients were 
included in both the Bleeding and Surgical Prophylaxis populations. 
BE, bleeding episode; N, number of patients
Patients excluded:
Not treated with HFC
(n = 8)
Patients screened*
(N = 33)
Patients treated†
(N = 25)
SAFETY population
(N = 25)
Surgical prophylaxis population
(N = 9)
12 surgeries
FAS-bleeding population
(N = 24)
89 BEs
TA B L E  1   Patient characteristics
 
N = 25
Mean ± SD Median (range)
Age at informed consent 
(years)
29.0 ± 13.0 27 (12-54)
Height (cm) 163.3 ± 11.7 165 (138-190)
Weight (kg) 67.2 ± 19.9 68 (28-101)
BMI (kg/m2) 25.0 ± 6.7 25.2 (12.6-39.6)
 n (%)
Age <18 years* 6 (24.0)
Sex
Male 14 (56.0)
Female 11 (44.0)
Race
White 19 (76.0)
Asian 5 (20.0)
Arab/Middle Eastern 1 (4.0)
Congenital fibrinogen deficiency
Afibrinogenemia 25 (100.0)
Abbreviations: BMI, body mass index; SD, standard deviation
*Age at first HFC infusion. 
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IDMEAC rated hemostatic efficacy as excellent for 81 BEs (91.0%), 
good for 7 (7.9%), and moderate for one (1.1%, based on a decrease 
in hemoglobin level, as per the objective rating scale; additional 
hemostatic intervention was not required in this patient). Treatment 
was therefore classified as success (rating of excellent or good) for 
96.6% (90% CI: 0.92-0.99) of patients by the investigator and 98.9% 
(90% CI: 0.95-0.999) by the IDMEAC (Figure 2).
For the subset of six adolescent patients (<18 years) with 11 
BEs, investigator-assessed hemostatic efficacy was rated excellent 
for 100% of BEs, while the IDMEAC assessed the treatment of 
72.7% of BEs as excellent and 27.3% as good. Treatment of all BEs 
(100%) was therefore categorized as successful in this population.
For the total Bleeding Population, there was a significant in-
crease in MCF tested in frozen plasma from 0 mm at baseline to 
1 hour after the first HFC infusion, with a mean (±SD) change of 
5.79 mm (±2.53; P < .001). For the six adolescent patients, mean 
(±SD) change in MCF for the 11 treated BEs was also significant 
(P < .001), but slightly lower, at 4.00 mm (±2.14). The mean value 
in adolescent patients included two postinfusion measurements 
of 0.0 mm, which were likely due to pre-analytical sample issues 
because there was a measurable plasma fibrinogen level in both 
cases. For all bleeds, the mean (SD) increase in MCF from base-
line to 1 hour postinfusion was 6.48 mm (3.07). An additional 
post hoc analysis was performed examining the relationship be-
tween MCF increase and age, body weight, or body surface area. 
Using a Pearson correlation from multilevel regression models, 
 
No. BEs/
surgeries
No. 
infusions
Mean ± SD (mg/
kg) Median (range) (mg/kg)
Bleeding (N = 24)
Dose of first 
infusion
89 89 61.88 ± 11.73 58.82 (32.12-102.60)
Dose per infusion 89 100 58.30 ± 15.45 57.47 (11.54-102.60)
Total dose per BE 89 100 65.51 ± 26.47 59.41 (32.12-273.80)
Total dose for major 
bleedsa
2 9 209.49 ± 90.94 209.49 (145.18-273.79)
Total dose for minor 
bleedsa
87 91 62.20 ± 11.31 58.82 (32.12-101.69)
Surgical prophylaxis (N = 9)
Total dose per 
surgery
12 31 104.49 ± 54.86b 85.80 (34.09-225.36)
Preoperative 
loading dose
12 11c 77.39 ± 20.22 70.00 (58.46-127.91)
Maintenance dose 12 20d 20.13 ± 7.49 16.97 (10.59-34.09)
Dose per infusion 12 31 40.45 ± 30.78 28.99 (10.59-127.91)
Abbreviations: BE, bleeding episode; SD, standard deviation.
aMinor bleeding was treated to achieve a recommended target fibrinogen plasma level of 100 mg/
dL, with a recommended lower limit of 80 mg/dL. Major bleeding was treated to achieve a 
recommended target fibrinogen plasma level of 150 mg/dL, with a recommended lower limit of 
130 mg/dL. 
bThe major surgery was treated with a total dose of 225.36 mg/kg via a preoperative loading dose 
plus seven maintenance infusions. 
cOne patient did not receive a loading dose for one surgery as they had received fibrinogen 
concentrate for treatment of a BE shortly beforehand and their plasma fibrinogen level was 
deemed to be acceptable. 
dAdministered across a total of six surgeries (five minor, one major). 
TA B L E  2   Summary of fibrinogen 
concentrate dosages for treatment 
of bleeding episodes and for surgical 
prophylaxis
F I G U R E  2   Efficacy of fibrinogen concentrate for on-demand 
treatment of bleeding episodes (Bleeding Population). *Two BEs 
with missing investigator assessments were adjudicated/scored by 
the IDMEAC. The success rate is a rating of excellent/good, with 
90% confidence intervals calculated according to Blyth–Still–Casella 
interval for the proportion of patients with successful hemostatic 
efficacy. N = 89 BEs in 24 patients. BE, bleeding episode; IDMEAC, 
independent data monitoring and endpoint adjudication committee
100 91.0%
78.7%
n = 81
n = 70
90
80
70
60
50
40
30
20
10
0
18.0%
7.9%
1.1%
n = 1 n = 1
1.1%
0.0 0.0
2.2%
n = 2 0.0
Missing*
n = 16
n = 7
NoneModerate
Efficacy rating
GoodExcellent
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 (%
)
Rated by investigator
Success rate: 96.6% (0.920-0.988)
Success rate: 98.9% (0.954-0.999)
Rated by IDMEAC
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the results suggested a significant association with change in 
MCF for both weight and body surface area (BSA; P < .001) but 
not for height (P = .05) or age (P = .46).
3.3 | Hemostatic efficacy for surgical prophylaxis
Nine patients received surgical prophylaxis for a total of 12 surger-
ies. Surgical procedures comprised one major (eye enucleation with 
socket reconstruction) and 11 minor (knee radioisotope synovec-
tomy [n = 2], dental extraction [n = 3], root canal operation [n = 1], 
circumcision [n = 2], excision of scar bud of circumcision [n = 1], skin 
biopsy [n = 1], and debridement of superficial necrosis [n = 1]).
A total of 31 infusions were administered for the 12 surgeries, with 
a median dose of 28.99 mg/kg HFC per infusion (Table 2). The median 
(range) dose per surgery was 85.80 mg/kg (34.09-225.36) and when 
considering only the 11 minor surgeries, was 78.57 mg/kg (34.09-
161.17). More than one infusion was administered for five of the minor 
surgeries, with a median (range) of three (1-4) maintenance infusions. 
Seven daily maintenance infusions were administered for the major 
surgery; these were given at the discretion of the treating physician 
based on assessment of the clinical situation even though the measured 
plasma fibrinogen levels were between 117 and 136 mg/dL over post-
operative Days 2-6.
Intraoperative and postoperative hemostatic prophylaxis was 
rated a success in 100% of cases by the investigator and IDMEAC 
(Figure 3). The individual intraoperative efficacy was rated as 
excellent for 91.7% and good for 8.3% of surgeries, by both the 
investigator and the IDMEAC. Postoperative efficacy was rated 
as excellent for 100% of surgeries by the investigator (Figure 3A 
and B); the IDMEAC rated postoperative efficacy as excellent 
for 91.7% of surgeries and good for 8.3%. Postoperative hemo-
static efficacy for the major surgery was classified as good by the 
IDMEAC, owing to postoperative oozing from the wound. Actual 
blood loss did not exceed the maximum expected blood loss, as 
assessed prior to surgery, for any procedure. In addition, no intra-
operative or postoperative transfusions were necessary.
3.4 | Fibrinogen level and in vivo recovery
Fibrinogen plasma level increased from baseline after HFC infusion in all 
patients for treatment of all BEs, reaching maximum values at 1 or 3 hours 
(Figure 4). The mean (±SD) fibrinogen level at 1 hour post-infusion was 
109.01 mg/dL (±24.38), with a median (range) of 109.00 mg/dL (0.00-
204.00), following a mean (±SD) first infusion dose of 61.88 mg/kg (±11.73). 
Four patients had post-infusion fibrinogen plasma levels below the lower 
limit of 80 mg/dL recommended for minor BEs, including one patient who 
was significantly under-dosed for the first BE (33.9 mg/kg; 54% of planned 
dose). One post-infusion fibrinogen value from the central laboratory was 
recorded as zero, likely due to pre-analytical sample issues, with the local 
laboratory analysis providing a value of 105.00 mg/dL at the same time 
point. Hemoglobin levels remained stable following HFC infusion for the 
majority of patients (Figure 4). A single patient, with a history of anemia, 
experienced a drop in hemoglobin of more than 20%. For the six adoles-
cent patients, the mean (±SD) fibrinogen level was 98.55 mg/dL (±10.43) at 
1 hour after the first HFC infusion for treatment of all 11 BEs.
The mean (±SD) incremental IVR calculated after the first infu-
sion of HFC for treatment of BEs was 1.82 mg/dL/[mg/kg] (±0.42). 
When calculated for the 11 BEs in the six adolescent patients, the 
mean was lower, at 1.29 mg/dL/[mg/kg] (±0.24). The mean (±SD) IVR 
calculated after the loading dose for each of the 11 surgeries was 
1.44 mg/dL/(mg/kg) (±0.58).
3.5 | Safety
In total, 91 AEs occurred in 19 patients (76.0%), of which, 43 AEs in 15 
patients were TEAEs. Three AEs in three patients were considered pos-
sibly related to treatment: a moderate AE reported as exacerbation of a 
F I G U R E  3   Efficacy of fibrinogen concentrate in surgical prophylaxis (Surgical Prophylaxis Population). A, Intraoperative efficacy; 
B, Postoperative efficacy. Surgical Prophylaxis population (N = 9; 12 surgeries). IDMEAC, independent data monitoring and endpoint 
adjudication committee. The success rate is a rating of excellent/good, with 90% confidence intervals calculated according to Blyth–Still–
Casella interval for the proportion of patients with successful hemostatic efficacy
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pre-existing condition of peripheral ischemia due to digital microthrombi, 
a mild skin reaction, and a mild AE reported as peripheral phlebitis of the 
upper limbs; all of which resolved (Table 3). The ischemia due to digital 
microthrombi was classified as a serious event. The patient presented 
with toe discoloration and pain 2 days after a 66.05 mg/kg (3962.7 mg) 
infusion of HFC and one day after an additional dose of 13.21 mg/kg 
(792.5 mg) for treatment of a minor BE (vaginal bleeding). The patient 
received treatment with acetylsalicylic acid and analgesics and reported 
that the discoloration was resolved two months later (full details of labo-
ratory data at each time point are given in Table S5). In total, 15 serious 
AEs were reported in five patients, one of which was considered possibly 
related to treatment (Table S6). There were no deaths during this study.
3.6 | Thrombogenicity markers
Fifteen patients had an increased level of prothrombin F1 + F2 at 
baseline. For five patients, levels appeared to increase following the 
first infusion of HFC. A single patient had an increased D-dimer level 
at baseline, with this remaining above the reference limit through-
out the study. Of the patients with normal levels at baseline, four 
had an increased level after the first HFC infusion. One patient 
with elevated thrombogenicity markers experienced a documented 
thrombotic event after treatment with HFC (ischemia due to digital 
microthrombi, as noted above).
3.7 | Immunogenicity
A positive antifibrinogen antibody test was obtained for six pa-
tients. In three patients, antibodies were already detected before 
the first HFC infusion. In the other three patients, antibodies 
were detected at various time points during the study. For these 
patients the positive testing was not constant and mostly at the 
threshold of positivity of the assay. In cases in which the test in-
dicated the presence of de novo antibodies, these did not appear 
F I G U R E  4   Change in plasma fibrinogen and hemoglobin levels before and after administration of fibrinogen concentrate for on-demand 
treatment of bleeding (Bleeding Population). Note that the number of available data values (N) diminishes markedly after Day 2 as most 
patients were only observed for this period. BE, bleeding episode; N, number of BEs for which data were available at the indicated time 
point; SE, standard error of the mean
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TA B L E  3   Summary of adverse events possibly or probably related to treatment
Event description Preferred term Serious (Yes/No) Severity Resolved (Yes/No) Causality
Mild skin reaction (itchiness and redness) Drug eruption No Mild Yes Possibly related
Ischemia due to digital microthrombi Thrombosis Yes Moderate Yes Possibly related
Peripheral phlebitis upper limbs Phlebitis No Mild Yes Possibly related
Note: Adverse events defined according to MedDRA version 18.1. MedDRA, Medical Dictionary for Regulatory Activities.
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to be neutralizing as there was no observable effect on fibrinogen 
levels or efficacy.
4  | DISCUSSION
This prospective, multinational study in patients with congenital fi-
brinogen deficiency represents the largest prospective data collec-
tion to date in this indication. HFC was successful in the treatment 
of BEs and as surgical prophylaxis, demonstrating adjudicated he-
mostatic efficacy (treatment success) for 98.9% of BEs and 100% of 
surgical procedures. In addition, the change in MCF from baseline, 
which has been used as a surrogate marker for hemostatic efficacy,18 
showed a statistically significant increase after treatment and was in 
good agreement with the efficacy rating given by the investigators 
and IDMEAC. A favorable safety profile was demonstrated, with no 
severe allergic or hypersensitivity reactions and no clinical evidence 
of de novo neutralizing antifibrinogen antibodies.
The high success rate for treatment of bleeding demonstrated 
here is comparable with that previously reported for other fibrin-
ogen concentrates. A retrospective analysis of 12 patients with 
congenital fibrinogen deficiency treated with Haemocomplettan® 
P rated hemostatic efficacy as very good (the highest rating) for all 
26 BEs; however, these data were based on a subjective scoring 
system without independent adjudication.9 In a postauthorization 
study of Clottafact®, five patients with afibrinogenemia received 
48 infusions for treatment of 49 hemorrhagic events, with efficacy 
rated as excellent for 27 and good for 21 infusions, giving a success 
rate (rating of excellent/good) of 100% using an objective 4-point 
scale.11
In the present study, the change in MCF from baseline to 1 hour 
after the first infusion of HFC was evaluated as a surrogate marker 
of efficacy. The statistically significant increase in MCF coincided 
with the 98.9% successful efficacy rating given by the IDMEAC, 
utilizing an objective 4-point scale. Manco-Johnson et al also 
demonstrated a statistically significant increase in MCF pre- and 
post-infusion of Haemocomplettan® P, using the same methodol-
ogy.10 In a comparison of the HFC investigated in the present study 
and Haemocomplettan® P, equivalent increases in MCF were ob-
served on administration of a single infusion of the respective fi-
brinogen concentrates.14 Taken together, data from previous studies 
demonstrate that MCF measured in plasma is suitable for use as a 
surrogate measure of efficacy in the administration of fibrinogen 
concentrate for treatment of bleeding in patients with congenital 
fibrinogen deficiency.
Six patients aged 12-17 years received HFC for treatment of a 
total of 11 BEs. Hemostatic efficacy was classified as successful for 
all BEs. There was also a significant increase in MCF from baseline to 
1 hour after HFC infusion in this population. These results suggest 
no difference in the efficacy of HFC for treatment of bleeding in 
the adult and the adolescent patients studied; however, the small 
number of patients aged <18 years that were enrolled, with none 
under 12 years, should be taken into consideration. Data regarding 
the response of adolescent and pediatric patients to fibrinogen 
concentrate are scarce, with previous studies not including a suf-
ficient number of patients to allow a meaningful comparison of the 
different age groups. A study evaluating Clottafact® as prophylaxis 
demonstrated clinical efficacy of 98.8% for patients aged under 
12 years and 100% for those aged 12 years or older; however, there 
were only four and five patients in these age groups, respectively.11
After administration of HFC, fibrinogen plasma level increased 
in all patients. The mean incremental IVR for HFC (1.82 mg/dL/[mg/
kg]) found in this study is comparable to those reported in an earlier 
PK study comparing it to Haemocomplettan® P (1.79 and 1.77 mg/
dL/[mg/kg], respectively).14 Manco-Johnson et al reported a simi-
lar value for Haemocomplettan® P (1.7 mg/dL/[mg/kg]).10 Kreuz et 
al calculated a slightly lower value of 1.5 mg/dL/[mg/kg]; however, 
the majority of patients received Haemocomplettan® P as routine 
prophylaxis or prior to surgery and so the results cannot be directly 
compared with those reported here.9
The HFC used in this study demonstrated 100% hemostatic ef-
ficacy (treatment rated as success) for surgical prophylaxis. Success 
rates were comparable with published data on Haemocomplettan® 
P, where fibrinogen concentrate was administered as prophylaxis for 
11 surgical procedures in patients with congenital fibrinogen defi-
ciency.9 Clinical efficacy based on subjective criteria was reported 
to be very good, which was the highest efficacy rating, for all but 
one surgery.
Of the 91 AEs that occurred in 19 patients, three were assessed 
as being possibly related to HFC. One of these was a thrombotic 
event, ie, ischemia due to digital microthrombi. This occurred 1 
day after the second infusion of HFC for treatment of a BE. This 
patient displayed elevated levels of prothrombin F1 + F2 prior to 
receiving HFC for treatment of all four BEs and the single surgery 
that they were treated for during the study, with variable levels 
post-infusion. Other fibrinogen concentrates have also been as-
sociated with thromboembolic events. A severe thrombosis of the 
subclavian vein was reported for a patient following intensifica-
tion of prophylactic treatment with Clottafact®,11 and a venous 
thrombosis and a nonfatal lung embolism were observed during 
treatment with Haemocomplettan® P.9 However, overall, the in-
cidence of thromboembolic events in patients treated with fibrin-
ogen concentrates is low.12 It should also be noted that patients 
with congenital fibrinogen disorders may experience thrombotic 
events in the absence of treatment with fibrinogen concentrate. 
Coagulation studies in vivo showed increased thrombus forma-
tion in the absence of fibrinogen in an afibrinogenaemic patient, 
with thrombi that were larger and more loosely packed than those 
formed with fibrinogen leaving patients potentially at thrombotic 
risk.19 Although this has mainly been noted for patients with 
dysfibrinogenemia, a number of cases have been reported for 
patients with hypo- or afibrinogenemia.20 It has been suggested 
that the absence of fibrinogen in blood may result in increased 
levels of other procoagulants, thereby increasing the general risk 
of thrombosis.20 Furthermore, data from a fibrinogen gene-knock-
out mouse model have shown that such thrombi are unstable,21 
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while increasing plasma fibrinogen levels by supplementation with 
fibrinogen concentrate may inhibit platelet adhesion and reduce 
the risk of thrombosis.20,22
Allergic or hypersensitivity reactions are a known risk of fibrin-
ogen and other coagulation factor concentrates, with anaphylactic 
shock, urticaria, and rash all having been previously reported.9,11,12,14 
In the present study, a single mild skin reaction was reported. The 
patient received treatment with diphenhydramine and hydrocorti-
sone and the event resolved. The same patient received two further 
HFC infusions, with prophylactic treatment with diphenhydramine 
and hydrocortisone administered each time, and did not experience 
any further reactions.
Because there is no standard test for fibrinogen inhibitors, an ex-
perimental nonstandard antifibrinogen ELISA was developed for the 
purpose of this study to identify the presence and/or development 
of antifibrinogen antibodies. Although a number of patients dis-
played positive results for such antibodies, none appeared to have 
neutralizing activity, with hemostatic efficacy and plasma fibrinogen 
level not being affected.
This large prospective study evaluating the treatment of con-
genital fibrinogen deficiency, an ultra-rare condition, showed that 
HFC is able to treat BEs and prevent surgical bleeding, leading 
to significant increases in fibrinogen blood levels and markers of 
global hemostasis. This study also used robust objective criteria 
for efficacy as well as adjudication by an independent commit-
tee of experts to assess the hemostatic efficacy for treatment of 
bleeding and for surgical prophylaxis. This assessment showed 
overwhelming success of the treatment in the patients studied. 
Limitations of the study included the relatively low number of ad-
olescent patients (n = 6), which made it difficult to identify any 
differences in efficacy between age groups. Given the low median 
age of the study, it is also a limitation that further differences in 
older age groups could not be identified, given concerns regard-
ing underlying thrombosis in older patients. The frequency and 
variability of bleeding symptoms reflects the variability seen in 
congenital fibrinogen deficiency, as despite low or no measur-
able fibrinogen levels, patients do not always experience frequent 
bleeding.2 The low numbers of major BEs and major surgeries 
might also be considered limitations, but the incidence of these 
is consistent with the ultra-rare setting and the nature of the dis-
order. With regard to the use of MCF as a surrogate measure of 
efficacy, a post hoc analysis identified a significant association 
with change in MCF for both weight and BSA but not for height 
or age. As this is a non-powered post hoc analysis, the significant 
P-values are likely to be the result of chance, as no pathophysio-
logical mechanism could be identified for this result.
In conclusion, this was the largest prospective study to date 
evaluating the treatment of patients with congenital fibrinogen 
deficiency. HFC was efficacious for on-demand treatment of 
bleeding and for surgical prophylaxis in patients with this condi-
tion. One patient experienced a single thrombotic event, while 
none experienced a severe allergic or hypersensitivity reaction 
and there was no clinical evidence of neutralizing antifibrinogen 
antibodies, demonstrating the favorable safety profile of the HFC 
used in this study.
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